|
DK2081929T3
(da)
|
2006-11-08 |
2013-04-15 |
Neurocrine Biosciences Inc |
Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
|
|
NZ591615A
(en)
|
2008-09-18 |
2012-07-27 |
Auspex Pharmaceuticals Inc |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US20120003330A1
(en)
*
|
2010-06-01 |
2012-01-05 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
JP6362601B2
(ja)
|
2012-09-18 |
2018-07-25 |
オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
EA202091397A1
(ru)
|
2013-01-31 |
2020-09-04 |
Ауспекс Фармацетикалс, Инк. |
Бензохинолоновые ингибиторы vmat2
|
|
CA2925562A1
(en)
*
|
2013-09-27 |
2015-04-02 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
AU2014357518A1
(en)
*
|
2013-12-03 |
2016-06-09 |
Auspex Pharmaceuticals, Inc. |
Methods of manufacturing benzoquinoline compounds
|
|
KR20160111999A
(ko)
|
2014-01-27 |
2016-09-27 |
오스펙스 파마슈티칼스, 인코포레이티드 |
소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
|
|
MX2016010213A
(es)
|
2014-02-07 |
2017-04-13 |
Auspex Pharmaceuticals Inc |
Formulaciones farmaceuticas novedosas.
|
|
US9782398B2
(en)
*
|
2014-02-07 |
2017-10-10 |
Neurocrine Biosciences, Inc. |
Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
|
|
LT3105218T
(lt)
|
2014-02-13 |
2019-12-10 |
Incyte Corp |
Ciklopropilaminai kaip lsd1 inhibitoriai
|
|
FI3936130T3
(fi)
*
|
2014-05-06 |
2024-04-23 |
Neurocrine Biosciences Inc |
Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
|
|
KR102586138B1
(ko)
*
|
2015-02-06 |
2023-10-05 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
[9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법
|
|
PL3265085T3
(pl)
|
2015-03-06 |
2022-11-07 |
Auspex Pharmaceuticals, Inc. |
Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
|
|
EA201792205A1
(ru)
|
2015-04-03 |
2018-02-28 |
Инсайт Корпорейшн |
Гетероциклические соединения как ингибиторы lsd1
|
|
US20190015396A1
(en)
*
|
2015-06-23 |
2019-01-17 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
DK3334709T3
(da)
|
2015-08-12 |
2025-02-03 |
Incyte Holdings Corp |
Salte af en lsd1-hæmmer
|
|
AR106313A1
(es)
|
2015-10-09 |
2018-01-03 |
Teva Pharmaceuticals Int Gmbh |
Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
|
|
DK3368534T3
(da)
*
|
2015-10-30 |
2021-02-15 |
Neurocrine Biosciences Inc |
Valbenazin-ditosylat og polymorfer deraf
|
|
DK3394057T3
(da)
*
|
2015-12-23 |
2022-04-11 |
Neurocrine Biosciences Inc |
Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
|
|
US10479787B2
(en)
|
2016-04-22 |
2019-11-19 |
Lupin Limited |
Process for preparation of tetrabenazine and deutetrabenazine
|
|
US10442800B2
(en)
*
|
2016-06-29 |
2019-10-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal forms of NBI-98854, preparation method and use thereof
|
|
AU2017340915B2
(en)
*
|
2016-10-06 |
2021-09-23 |
Assia Chemical Industries Ltd. |
Solid state forms of valbenazine
|
|
TW202515564A
(zh)
|
2016-12-02 |
2025-04-16 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
EP3568394A1
(en)
|
2017-01-10 |
2019-11-20 |
Sandoz AG |
Crystalline valbenazine free base
|
|
KR20230170136A
(ko)
*
|
2017-01-27 |
2023-12-18 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
CA3054238A1
(en)
|
2017-02-27 |
2018-08-30 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
TWI772382B
(zh)
|
2017-03-15 |
2022-08-01 |
美商奧斯拜客斯製藥有限公司 |
氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
CN110691596A
(zh)
*
|
2017-04-01 |
2020-01-14 |
阿德普蒂奥制药有限公司 |
药物组合物
|
|
GB201705303D0
(en)
*
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
CA3076000A1
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
US20200230127A1
(en)
*
|
2017-10-10 |
2020-07-23 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
CA3081709A1
(en)
*
|
2017-11-08 |
2019-05-16 |
Yuhua Li |
Esters of dihydrotetrabenazine
|
|
AU2018371771B2
(en)
|
2017-11-22 |
2024-06-20 |
Assia Chemical Industries Ltd |
Solid state form of Valbenazine
|
|
KR102447769B1
(ko)
|
2017-12-26 |
2022-09-26 |
크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. |
발베나진 토실산염의 결정형 및 그 제조 방법 및 용도
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
JOP20200298A1
(ar)
*
|
2018-06-14 |
2020-11-22 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
CN114302883B
(zh)
*
|
2019-08-12 |
2022-09-06 |
山东绿叶制药有限公司 |
Vmat2抑制剂及其制备方法和应用
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
US20220363680A1
(en)
|
2019-09-13 |
2022-11-17 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
PE20240822A1
(es)
|
2021-03-22 |
2024-04-18 |
Neurocrine Biosciences Inc |
Inhibidores de vmat2 y metodos de uso
|
|
EP4330255A1
(en)
|
2021-04-26 |
2024-03-06 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
CA3221728A1
(en)
|
2021-06-30 |
2023-01-05 |
Grace S. LIANG |
Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
|
|
IL309172A
(en)
|
2021-06-30 |
2024-02-01 |
Neurocrine Biosciences Inc |
Vulbanazine for use in the additional treatment of schizophrenia
|
|
CA3245030A1
(en)
|
2022-03-07 |
2023-09-14 |
Neurocrine Biosciences, Inc. |
VALBENAZINE, A VMAT2 INHIBITOR, AS A FREE BASE OF A TOSYLATE OR DITOSYLATE SALT, INTENDED FOR USE IN THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
|
|
KR20250083502A
(ko)
|
2022-09-21 |
2025-06-10 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
헥사히드로-2h-피리도[2,1-a]이소퀴놀린 vmat2 억제제 및 사용 방법
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
TW202521119A
(zh)
|
2023-08-17 |
2025-06-01 |
美商紐羅克里生物科學有限公司 |
用於投與特定vmat2抑制劑之方法
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|
|
WO2026050236A1
(en)
|
2024-08-27 |
2026-03-05 |
Neurocrine Biosciences, Inc. |
Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder
|
|
WO2026126112A1
(en)
|
2024-12-10 |
2026-06-18 |
Lupin Limited |
Liquid compositions of valbenazine for oral administration
|